Manufacturing and Marketing. Neither the Company nor any of its Subsidiaries has granted rights to manufacture, produce, assemble, license, market, or sell their Products to any other person and is not bound by any agreement that affects the Company's or any of its Subsidiaries exclusive right to develop, manufacture, assemble, distribute, market or sell their Products.
Manufacturing and Marketing. 10 5.1. Pre-Clinical and Clinical Manufacture by Celtrix.............. 10 5.2. Commercial Manufacture by Genzyme............................. 10 5.3.
Manufacturing and Marketing. 5.1. Pre-Clinical and Clinical Manufacture by Celtrix. Subject to ------------------------------------------------ Genzyme's rights under Section 5.3, Celtrix shall be responsible for manufacturing all of Genzyme's requirements for Product for the conduct of pre- clinical and Phase I/II clinical testing of the Initial Products provided that Celtrix possesses the capability to perform such manufacturing under applicable regulatory standards and that it shall have adequate capacity to provide the necessary quality and quantity of Product in the time frames required by Genzyme. The parties shall agree to and implement customary forecast and order procedures with respect to such Product to be manufactured by Celtrix. Celtrix's responsibilities shall include all aspects of the manufacturing process, including maintenance of manufacturing inventory, quality control and shipment of Product in accordance with orders placed by Genzyme. As compensation for such manufacturing services, Celtrix shall be entitled to receive payment of its Manufacturing Costs, subject to reduction pursuant to Section 3.2(c).
Manufacturing and Marketing. DESIGNER will have no responsibility for tooling, manufacturing or marketing relating to the Products.
Manufacturing and Marketing. (a) PFIZER shall have sole responsibility for approving the Contract Manufacturer (including itself) to create Raw Material and/or Licensed Product. PFIZER agrees to consider an assignment by IMMUCELL of that certain Contract Manufacture Agreement between IMMUCELL and [* * *] in draft form dated March 19, 2003 (the “[* * *] Agreement”), taking into account PFIZER’s supply and quality requirements, but reserves the right to condition any such assignment and assumption by PFIZER on [* * *] making such amendments to the [* * *] Agreement as may be requested by PFIZER in its sole discretion with prior notice to IMMUCELL. IMMUCELL agrees to cooperate with PFIZER in furtherance of any such negotiations. In the event PFIZER or [* * *] declines any such assignment or assumption for any reason, and provided that PFIZER does not in connection therewith enter into any similar replacement agreement with [* * *] IMMUCELL shall bear any costs of terminating the [* * *] Agreement.
Manufacturing and Marketing. The Company's ability to operate profitably in the cellular collection cancer diagnostic market will depend on the successful transfer of its proprietary technology to commercial-scale creation of both product and process of the InPath System. There can be no assurance that the Company will not incur substantial cost overruns and delays in preparing product for the marketplace. Additionally, there can be no assurance that the Company's proprietary technology can or will be successfully commercialized.
Manufacturing and Marketing. Pursuant to the license set forth in Section 2.1, NitroMed has the exclusive right to manufacture, market and commercialize Collaboration Products during the term of this Agreement, and shall have full autonomy over all decisions relating thereto.
Manufacturing and Marketing. 7.1 HP will perform all manufacture, reproduction and assembly of the Programs and Documentation.
Manufacturing and Marketing. (a) BioTime and Summit shall collaborate to find an appropriate licensee to manufacture and market a Product in the Territory in the late development stages or for marketing. Summit shall inform BioTime of its wishes to commence searching together for a licensee, but in no event later than the NDA (or Japanese equivalent) filings of Hextend and PentaLyte, respectively, in the Territory.
Manufacturing and Marketing. 6.1 Caere shall deliver a gold master of the Program(s) and an electronic copy of the Documentation to HP in accordance with the Milestones set forth in Exhibit C, or, as applicable, the Project Schedules as outlined in Exhibit B. *CONFIDENTIAL TREATMENT REQUESTED
